CN102988629A - Medicine used for treating fatty liver - Google Patents
Medicine used for treating fatty liver Download PDFInfo
- Publication number
- CN102988629A CN102988629A CN 201110265757 CN201110265757A CN102988629A CN 102988629 A CN102988629 A CN 102988629A CN 201110265757 CN201110265757 CN 201110265757 CN 201110265757 A CN201110265757 A CN 201110265757A CN 102988629 A CN102988629 A CN 102988629A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- parts
- portions
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine used for treating fatty liver. The medicine is composed of traditional Chinese medicine raw materials such as Mongolian milkvetch root, pilose asiabell root, obtuseleaf senna seed, hawthorn, salvia miltiorrhiza, panax notoginseng, white peony root, oriental waterplantain tuber, tuckahoe, licorice root, and the like. The medicine has the functions of qi invigorating, blood circulation invigorating, dampness eliminating, and fat reducing. The medicine is used for treating fatty liver. A total effective rate of the medicine is 95%, and a curative rate is 53.5%, which are substantially higher than those of existing medicines.
Description
Technical field
The present invention relates to a kind of Chinese medicine, specifically a kind of fatty liver medicine for the treatment of.Belong to field of medicaments.
Background technology
Fatty liver is that the liver fat that a variety of causes causes is accumulated too much pathological state.Accumulate when the hepatocyte inner lipid and to surpass 5%, or during the upper per unit area 1/3 above liver cell fatty degeneration of histology, be called fatty liver, its pathogenesis is not yet clear and definite so far.Modern medicine is thought may be relevant with many factors, plays a role in its pathogenic process such as abnormalities of sugar/lipid metabolism, hormonal readiness change, E﹠H factor, lipid peroxidation damage, immunoreation, anoxia and hepatic circulatory disturbance etc.The pathological changes of fatty liver is the reversibility pathological changes, can return to one's perfect health under diagnosis and the rational therapy in early days.Such as untimely treatment, the part Patients with Fatty Liver can develop into hepatic fibrosis, so even liver cirrhosis can think that fatty liver is the cercinoma prophase pathologic change of hepatic fibrosis and liver cirrhosis.
Along with the raising of people's living standard, in rising trend by the fatty liver that Bad Eating Habit cause in recent years.Western medicine is take blood fat reducing as main, and curative effect is not ideal.And adopt the obtained curative effect of TCM Therapy satisfactory.
Summary of the invention
Purpose of the present invention just provides a kind of medicine for the treatment of fatty liver, and it can regulate the balance of health own, treats fatty liver from its morbidity root.
For achieving the above object, the medicine for the treatment of fatty liver provided by the invention is prepared from by the processing of the crude drug of following weight parts:
Radix Astragali 20-30 part Radix Codonopsis 10-20 part Semen Cassiae 10-20 part Fructus Crataegi 10-20 part
Radix Salviae Miltiorrhizae 8-15 part Radix Notoginseng 8-15 part Radix Paeoniae Alba 10-20 part Rhizoma Alismatis 5-15 part
Poria 5-15 part Radix Glycyrrhizae 5-10 part.
Preferred plan is prepared from by the processing of the crude drug of following weight parts:
15 parts of 15 portions of Fructus Crataegis of 15 parts of Semen Cassiaes of 25 parts of Radix Codonopsis of the Radix Astragali
10 parts of 12 portions of Rhizoma Alismatis of 15 portions of Radix Paeoniae Albas of 12 portions of Radix Notoginseng of Radix Salviae Miltiorrhizae
8 parts in 10 portions of Radix Glycyrrhizaes of Poria.
Why the present invention selects above-mentioned medical material as raw material, is because they have following effect:
The Radix Astragali: sweet, temperature.Return lung, spleen channel.Invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.It is weak to be used for the deficiency of vital energy, anorexia and loose stool, and sinking of QI of middle-JIAO, the chronic diarrhea proctoptosis, the metrorrhagia of having blood in stool, the exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle is difficult bursts, and burst for a long time and do not hold back, the blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes.
Radix Codonopsis: sweet in the mouth is flat.Return spleen, lung meridian.Invigorating the spleen and replenishing QI, the spleen invigorating lung benefiting is used for deficiency of the spleen and lung, the cardiopalmus of breathing hard, anorexia and loose stool, the dyspnea due to deficiency cough, interior-heat is quenched one's thirst.
Semen Cassiae: sweet, bitter, salty, be slightly cold.Return liver, large intestine channel.Clearing away heat to improve acuity of vision, loosening bowel to relieve constipation.Be used for the puckery pain of conjunctival congestion, the many tears of photophobia, it is dizzy to have a headache, poor vision, constipation.
Fructus Crataegi: sour, sweet, tepor.Return spleen, stomach, Liver Channel.Promoting digestion and invigorating the stomach, the circulation of qi promoting dissipating blood stasis.Be used for meat stagnation, gastral cavilty distension, dysentery stomachache, blood stasis amenorrhea, postpartum stagnation, trusted subordinate's twinge, hernia pain; Hyperlipidemia.
Radix Salviae Miltiorrhizae: hardship is slightly cold.GUIXIN, Liver Channel.Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, relieving restlessness clears away heart-fire.Be used for menoxenia, amenorrhea dysmenorrhea , lumps in the chest and abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection swells and ache, dysphoria and insomnia; Hepatosplenomegaly, angina pectoris.
Radix Notoginseng: dissipating blood stasis hemostasis, subduing swelling and relieving pain.Be used for spitting of blood, spit blood, epistaxis is had blood in stool, metrorrhagia, and traumatic hemorrhage, the breast abdomen twinges, tumbling and swelling.
The Radix Paeoniae Alba: bitter, sour, be slightly cold.Return liver, spleen channel.The suppressing the hyperactive liver pain relieving, nourishing blood for regulating menstruation, astringing YIN to stop sweating.It is dizzy to be used for having a headache, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat.
Rhizoma Alismatis: sweet, cold.Return kidney, urinary bladder channel.Diuresis, clearing away damp-heat.Be used for dysuria, edema distension, the oliguria of having loose bowels, dizziness due to fluid-retention, the puckery pain of pyretic stranguria; Hyperlipidemia.
Poria: sweet, light, flat; GUIXIN, lung, spleen, kidney channel.Promoting diuresis to eliminate damp pathogen, the spleen invigorating mind calming.Be used for the edema oliguria, the phlegm retention vertigo and palpitation, insufficiency of the spleen lack of appetite, have loose bowels in the loose stool, irritability, palpitation with fear insomnia.
Radix Glycyrrhizae: and middle emergency, lung moistening, detoxifcation, coordinating the actions of various ingredients in a prescription.
Medicine provided by the invention has the effect of inrigorating qi and promoting blood circulation, dampness removing blood fat reducing, is used for the treatment of clinically fatty liver.
The specific embodiment
Below with embodiment a kind of medicine for the treatment of fatty liver of the present invention is further described, this will help the present invention and effect thereof are further understood, embodiment does not limit protection scope of the present invention, its protection domain is decided by claim.
Embodiment 1
10 parts of 10 portions of Fructus Crataegis of 10 parts of Semen Cassiaes of 20 parts of Radix Codonopsis of the Radix Astragali
5 parts of 10 portions of Rhizoma Alismatis of 8 portions of Radix Paeoniae Albas of 8 portions of Radix Notoginseng of Radix Salviae Miltiorrhizae
5 parts in 5 portions of Radix Glycyrrhizaes of Poria.
Embodiment 2
20 parts of 20 portions of Fructus Crataegis of 20 parts of Semen Cassiaes of 30 parts of Radix Codonopsis of the Radix Astragali
15 parts of 20 portions of Rhizoma Alismatis of 15 portions of Radix Paeoniae Albas of 15 portions of Radix Notoginseng of Radix Salviae Miltiorrhizae
10 parts in 15 portions of Radix Glycyrrhizaes of Poria
Embodiment 3
15 parts of 15 portions of Fructus Crataegis of 15 parts of Semen Cassiaes of 25 parts of Radix Codonopsis of the Radix Astragali
10 parts of 12 portions of Rhizoma Alismatis of 15 portions of Radix Paeoniae Albas of 12 portions of Radix Notoginseng of Radix Salviae Miltiorrhizae
8 parts in 10 portions of Radix Glycyrrhizaes of Poria
Clinical trial:
One, case inclusion criteria: select outpatient's 120 examples, matched group 60 examples, medicine group 60 examples of the present invention.
Two, diagnosis basis: all cases all belongs to following 5 conditions, 1. body obesity, and the history of being addicted to drink, or history of virus hepatitis is arranged; 2. liver increases, the medium increase of matter; 3. the glutamate pyruvate transaminase moderate is unusual; 4. blood fat obviously increases; 5. ultrasound diagnosis prompting liver increases.
Two groups of patients all have obesity in various degree, weak, loss of appetite, abdominal distention, hypochondriac pain, feel sick, belch, wherein jaundice appears in minority; And two groups of ages, sex, the course of disease, the state of an illness, medical histories are similar, and have comparability.
Therapeutic Method: treatment group adopts embodiment 3 prescriptions of medicine of the present invention, get Radix Astragali 250g, Radix Codonopsis 150g, Semen Cassiae 150g, Fructus Crataegi 150g, Radix Salviae Miltiorrhizae 120g, Radix Notoginseng 150g, Radix Paeoniae Alba 120g, Rhizoma Alismatis 100g, Poria 100g, Radix Glycyrrhizae 80g add 6 times of water gagings and decoct 2 times, each 1 hour, filter, merging filtrate is condensed into the extractum that relative density is 1.10-1.15; Add appropriate amount of starch, drying is pulverized, and filled capsules is made 1000, every capsules dress 0.5g.Each serving using 6 of capsules, every day 3 times, 2 months is a course for the treatment of, takes continuously 3 courses for the treatment of.Matched group takes the Western medicine fenofibrate, and 1 of every day, 2 months was 1 course for the treatment of, took continuously 3 courses for the treatment of.Two groups of period in a medicine are withdrawn other medicines, check contrast after taking the course for the treatment of.
Two groups of period in a medicine were observed symptom and feature 1 time in per 20 days; Check liver function every month 1 time, and do ultrasound diagnosis.After taking 3 courses for the treatment of, carry out comprehensive review, judge curative effect.
Curative effect determinate standard: 1. liver bounces back to normally; 2. liver function recovery is normal; 3. blood fat all is down to normal range; 4. ultrasound diagnosis fatty liver ultrasonogram recovers normal; 5. clinical symptom disappearance.
Recovery from illness: after treating 3 courses for the treatment of, 5 curative effect index all reach.
Produce effects: in 5 indexs, reach 3~4.
Effectively: in 5 indexs, reach 2.
Invalid: as in 5 indexs, to reach 1 or without the changer.
Clinical drug curative effect comparision table of the present invention
Two groups of total effective rates: treatment group 95%; Matched group 86.7%.No significant difference (p>0.05).Cure rate: treatment group is 53.3%, and matched group is 20%, and notable difference (p<0.05) is arranged.
Medical record is given an example:
Lee, the woman, 35 years old, the business personnel, 2008 are medical.The patient felt weak over 1 year, and oil is detested in dizzy hyperhidrosis, dull pain in liver, and more so, large loose stool accompanies indigestion food every day 3~4 times after the fatigue, and the light amount of menstruation color is few, pyknic type, shallow complexion, pale tongue, the tip of the tongue, there is petechia on the tongue limit, thready and hesitant pulse.Lab testing: glutamate pyruvate transaminase 124IU/L, triglyceride 6.2mmol/L, cholesterol 9.6 mmol/L.The B ultrasonic prompting: 4.2cm under the liver rib, 3.7cm under the xiphoid-process, the margo interior hepatis rust, the liver inner structure is fuzzy, and the nearly sound of echo strengthens, and primary sound is weak, is diagnosed as fatty liver, comprehensive analysis to both pulse manifestation and symptoms, damp-retention due to hypofunction of the spleen, expectorant silt alternate, the liver failing to maintain the normal flow of QI are stopped up resistance liver network.With 3 courses for the treatment of of medicine of the present invention, to check after taking the course for the treatment of, liver function, blood fat, cholesterol are all normal.B ultrasonic shows: the degeneration of liver fat-like disappears, and followed up a case by regular visits to, ANOMALOUS VARIATIONS is not arranged in 1 year
Claims (2)
1. pharmaceutical composition for the treatment of fatty liver is characterized in that being prepared from by the crude drug processing of following weight parts:
Radix Astragali 20-30 part Radix Codonopsis 10-20 part Semen Cassiae 10-20 part Fructus Crataegi 10-20 part
Radix Salviae Miltiorrhizae 8-15 part Radix Notoginseng 8-15 part Radix Paeoniae Alba 10-20 part Rhizoma Alismatis 5-15 part
Poria 5-15 part Radix Glycyrrhizae 5-10 part.
2. the pharmaceutical composition for the treatment of fatty liver according to claim 1 is characterized in that being prepared from by the crude drug processing of following weight parts:
15 parts of 15 portions of Fructus Crataegis of 15 parts of Semen Cassiaes of 25 parts of Radix Codonopsis of the Radix Astragali
10 parts of 12 portions of Rhizoma Alismatis of 15 portions of Radix Paeoniae Albas of 12 portions of Radix Notoginseng of Radix Salviae Miltiorrhizae
8 parts in 10 portions of Radix Glycyrrhizaes of Poria.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110265757 CN102988629A (en) | 2011-09-08 | 2011-09-08 | Medicine used for treating fatty liver |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110265757 CN102988629A (en) | 2011-09-08 | 2011-09-08 | Medicine used for treating fatty liver |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102988629A true CN102988629A (en) | 2013-03-27 |
Family
ID=47918059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110265757 Pending CN102988629A (en) | 2011-09-08 | 2011-09-08 | Medicine used for treating fatty liver |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102988629A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104587098A (en) * | 2015-02-04 | 2015-05-06 | 蔡炜 | Medicament for treating fatty liver |
CN106174554A (en) * | 2016-08-12 | 2016-12-07 | 贵州省玉屏县金心笛油脂开发有限公司 | A kind of fragrance of osmanthus Oleum Camelliae and preparation method thereof |
CN106262890A (en) * | 2016-08-12 | 2017-01-04 | 贵州省玉屏县金心笛油脂开发有限公司 | A kind of tea oil health-care product with hypolipemic function and preparation method thereof |
CN107050380A (en) * | 2017-02-20 | 2017-08-18 | 成都富豪斯生物科技有限公司 | A kind of Chinese medicine composition for treating fatty liver and hyperlipidemia and preparation method thereof |
CN107080771A (en) * | 2017-04-12 | 2017-08-22 | 吉林省德葆康医药科技股份有限公司 | Treat Chinese medicine composition of hyperlipidemia and fatty liver and preparation method thereof |
CN107224558A (en) * | 2017-06-13 | 2017-10-03 | 江苏黄河药业股份有限公司 | It is a kind of to treat ginseng stilbene preparation of fatty liver and preparation method thereof |
CN107281441A (en) * | 2017-06-13 | 2017-10-24 | 江苏黄河药业股份有限公司 | Preparation of one seed ginseng stilbene tonifying liver stomach invigorating invigorating the spleen and preparation method thereof |
-
2011
- 2011-09-08 CN CN 201110265757 patent/CN102988629A/en active Pending
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104587098A (en) * | 2015-02-04 | 2015-05-06 | 蔡炜 | Medicament for treating fatty liver |
CN106174554A (en) * | 2016-08-12 | 2016-12-07 | 贵州省玉屏县金心笛油脂开发有限公司 | A kind of fragrance of osmanthus Oleum Camelliae and preparation method thereof |
CN106262890A (en) * | 2016-08-12 | 2017-01-04 | 贵州省玉屏县金心笛油脂开发有限公司 | A kind of tea oil health-care product with hypolipemic function and preparation method thereof |
CN107050380A (en) * | 2017-02-20 | 2017-08-18 | 成都富豪斯生物科技有限公司 | A kind of Chinese medicine composition for treating fatty liver and hyperlipidemia and preparation method thereof |
CN107080771A (en) * | 2017-04-12 | 2017-08-22 | 吉林省德葆康医药科技股份有限公司 | Treat Chinese medicine composition of hyperlipidemia and fatty liver and preparation method thereof |
CN107224558A (en) * | 2017-06-13 | 2017-10-03 | 江苏黄河药业股份有限公司 | It is a kind of to treat ginseng stilbene preparation of fatty liver and preparation method thereof |
CN107281441A (en) * | 2017-06-13 | 2017-10-24 | 江苏黄河药业股份有限公司 | Preparation of one seed ginseng stilbene tonifying liver stomach invigorating invigorating the spleen and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103908640B (en) | A kind of Chinese medicine composition for the treatment of cirrhosis | |
CN102988629A (en) | Medicine used for treating fatty liver | |
CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
CN103751281A (en) | Traditional Chinese medicinal composition for treating ascites due to cirrhosis | |
CN104740041A (en) | Traditional Chinese medicine oral decoction for treating constipation | |
CN103316317A (en) | Traditional Chinese medicine composition for treating superficial gastritis | |
CN105535390A (en) | Traditional Chinese medicine decoction for treating coronary heart disease and preparation method of traditional Chinese medicine decoction | |
CN103417834A (en) | Selenium-rich radix astragali heart-protection oral liquid | |
CN103142844A (en) | Pharmaceutical composition for treating diabetic nephropathy | |
CN102366617A (en) | Chinese patent medicine for treating idiopathic edema | |
CN105381424A (en) | Traditional Chinese medicine for detoxifying human viscera and preparation method of traditional Chinese medicine | |
CN104689218A (en) | Traditional Chinese medicine composition for treating fatty liver | |
CN101181451B (en) | Chinese medicine prescription orally taken for curing chronic atrophic gastritis | |
CN100502928C (en) | Traditional Chinese medicine composition for treating hepatocirrhosis and liver ascites | |
CN103285343A (en) | Medicine for treating liver cancer and preparation method thereof | |
CN102935214B (en) | Traditional Chinese medicinal composition for treating uremia | |
CN105435131A (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
CN103494939A (en) | Traditional Chinese medicine for treating senile habitual constipation | |
CN104258351A (en) | Traditional Chinese medicine preparation for treating alcoholic cardiomyopathy and preparation method of preparation | |
CN104013881A (en) | Blood lipid-reducing health-care tea bag | |
CN103656199B (en) | A kind of Chinese medicine for the treatment of deficiency of kidney yin syndrome cough | |
CN102335398A (en) | Traditional Chinese medicine formula for treating hyperlipidemia | |
CN101693096A (en) | Medicament for treating liver cancer and preparation method thereof | |
CN106581425A (en) | Pharmaceutical composition for treating | |
CN105726695A (en) | Medicine composition for treating chronic superficial gastritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130327 |